These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8899700)

  • 1. Muscarinic receptors in Alzheimer's disease.
    Pavía J; de Ceballos ML; Sánchez de la Cuesta F
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():71-5. PubMed ID: 8899700
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters.
    Muma NA; Mariyappa R; Williams K; Lee JM
    Synapse; 2003 Jan; 47(1):58-65. PubMed ID: 12422374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease.
    Shiozaki K; Iseki E
    J Neurol Sci; 2004 Aug; 223(2):145-8. PubMed ID: 15337615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: A needle from the haystack.
    Morris R; Mucke L
    Nature; 2006 Mar; 440(7082):284-5. PubMed ID: 16541054
    [No Abstract]   [Full Text] [Related]  

  • 5. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular amyloid-beta in Alzheimer's disease.
    LaFerla FM; Green KN; Oddo S
    Nat Rev Neurosci; 2007 Jul; 8(7):499-509. PubMed ID: 17551515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
    Schmidt AM; Sahagan B; Nelson RB; Selmer J; Rothlein R; Bell JM
    Curr Opin Investig Drugs; 2009 Jul; 10(7):672-80. PubMed ID: 19579173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of central galanin administration on muscarinic cholinergic and galanin receptor G protein coupling.
    Barreda-Gómez G; Giralt MT; Rodríguez-Puertas R
    Neuropeptides; 2005 Jun; 39(3):157-60. PubMed ID: 15944005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease. A partner for presenilin.
    Schenk D
    Nature; 2000 Sep; 407(6800):34-5. PubMed ID: 10993060
    [No Abstract]   [Full Text] [Related]  

  • 10. Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins.
    Pavía J; de Ceballos ML; Sanchez de la Cuesta F
    Fundam Clin Pharmacol; 1998; 12(5):473-81. PubMed ID: 9794144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol homeostasis and the pathophysiology of Alzheimer's disease.
    Blain JF; Poirier J
    Expert Rev Neurother; 2004 Sep; 4(5):823-9. PubMed ID: 15853509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal.
    Sayre LM; Zagorski MG; Surewicz WK; Krafft GA; Perry G
    Chem Res Toxicol; 1997 May; 10(5):518-26. PubMed ID: 9168248
    [No Abstract]   [Full Text] [Related]  

  • 13. Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation.
    Sola Vigo F; Kedikian G; Heredia L; Heredia F; Añel AD; Rosa AL; Lorenzo A
    Neurobiol Aging; 2009 Sep; 30(9):1379-92. PubMed ID: 18187234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of Alzheimer's Abeta peptide: the many roads to perdition.
    Tanzi RE; Moir RD; Wagner SL
    Neuron; 2004 Sep; 43(5):605-8. PubMed ID: 15339642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Klunk WE; Mathis CA; Price JC; Lopresti BJ; DeKosky ST
    Brain; 2006 Nov; 129(Pt 11):2805-7. PubMed ID: 17071918
    [No Abstract]   [Full Text] [Related]  

  • 16. Clearing amyloid through the blood-brain barrier.
    Zlokovic BV
    J Neurochem; 2004 May; 89(4):807-11. PubMed ID: 15140180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease therapeutics: new approaches to an ageing problem.
    Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI
    IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-amyloid: Alzheimer's disease and brain beta-amyloidoses.
    Koudinova NV; Berezov TT; Koudinov AR
    Biochemistry (Mosc); 1999 Jul; 64(7):752-7. PubMed ID: 10424897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism.
    Petratos S; Li QX; George AJ; Hou X; Kerr ML; Unabia SE; Hatzinisiriou I; Maksel D; Aguilar MI; Small DH
    Brain; 2008 Jan; 131(Pt 1):90-108. PubMed ID: 18000012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [beta-amyloidogenesis].
    Ihara Y
    Rinsho Shinkeigaku; 1997 Dec; 37(12):1100-1. PubMed ID: 9577656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.